Seres Therapeutics Inc MCRB

$2.94 +0.01 (0.34%)

Valuation

Market cap
29,432,000
Revenue TTM
$790,000
Net income TTM
$5,700,000
PE ratio
0.00
Forward PE
—
Profit margin
721.52%
Debt to equity
0.00

Trading

Volume
100,900
Avg volume
65,356
Day's range
$2.91 – $3.20
Shares out
10,045,000
Stochastic %K
8%
Beta
0.31
Analysts
Strong Sell
Price target
$17.00

Price

Company profile

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allo...

Show more

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 945 9626
Website
https://www.serestherapeutics.com
Address
101 Cambridgepark Drive, Cambridge, United States

Latest news

Stocktwits

biotech92 Oct 3, 12:58 PM
$MCRB In full agreement. It is clearly way, way oversold. Any update of any kind that is even remotely positive gets a very nice bounce or so we are fully convinced after very careful, extensive due diligence trying to see if there is something we were missing that explained the carnage of the stock price. Work completed. Oh, btw, Q4 'Tis the Season for biotech M&A.
0 replies
CMJensen Oct 3, 12:53 PM
$MCRB $XBI $IBB
0 replies
GettingBigNP Oct 3, 12:33 PM
$MCRB $XBI $IBB The more I look at MCRB down here, the more the asymmetry stands out. The market has already delivered the punishment. All-time lows. Extreme oversold conditions. Destroyed sentiment. Management credibility near zero. A valuation that suggests very little is expected to go right. Yet the actual opportunity hasn’t vanished. 🧬 SER-155 — allo-HSCT + irEC 🧬 SER-428 — scalable next-gen formulation 🧬 SER-603 🧬 SER-147 🤝 Potential partnerships 💰 Multiple strategic/financing paths You don’t need everything to work. You need one meaningful development to make the market reconsider what this entire platform is worth. That’s what interests me. Maximum pessimism on the screen while potentially meaningful catalysts remain off the screen. The chart tells you what happened. It doesn’t tell you what happens next. 👀 Daily RSI reaching extreme oversold territory and what looked like capitulation this week.. I have a hard time imagining we don’t see a meaningful bounce next week.
0 replies
Thewolf76 Oct 2, 2:29 PM
$MCRB This stock should be at $40, WHAT the hell is going on?
1 replies
Neptune1870 Oct 2, 2:27 PM
$MCRB we’re waiting for the rally…
0 replies
Neptune1870 Oct 2, 1:21 PM
$MCRB Green today
1 replies
GettingBigNP Oct 2, 12:20 PM
$MCRB $MRK $AZN $BMY The TAM estimates in the post reshared below are RISK-ADJUSTED. This isn’t the blue-sky bull case where SER-155/428/603/147 captures everything remotely addressable. Once you start looking at the full potential across allo-HSCT, irEC and future expansion, the bull-case opportunity could reach into the BILLIONS. Now compare that potential with what Seres has today: ✅ No debt ✅ Cash runway through Q1 2027 ✅ Breakthrough Therapy + Fast Track designations ✅ Strong SER-155 data ✅ Expansion into irEC, with management engaging potential partners, including companies with ICI franchises ✅ Management is considering sources of financing while evaluating the next steps for SER-155, suggesting they have multiple paths available to advance ✅ Directors chose stock options instead of annual cash compensation, further aligning themselves with shareholders Risk-adjusted TAM already dwarfs today’s valuation. The full bull case? Potentially BILLIONS. That’s why I’m here.
0 replies
GettingBigNP Oct 2, 11:45 AM
$MCRB $XBI $IBB is trading like the pipeline is worth literally nothing. Let’s actually look at what Seres owns: 🧬 SER-155 allo-HSCT: Phase 2 ready, Breakthrough Therapy + Fast Track, 77% relative reduction in bacterial BSIs in Ph1b. I’d argue $150–300M+ today. 🎗️ SER-155 irEC: 80% immunosuppressive-free response at Day 15 in the MSK study. Potentially enormous oncology application with ICI companies already being approached as partners. $150–300M+ today. 💧 SER-428: Liquid SER-155-based therapy targeting high-risk ICU/AMR patients. CARB-X funded, IND-enabling work underway. $25–75M. 🔥 SER-603: Next-gen LBP for ulcerative colitis/Crohn’s, IND-enabling with partnership discussions. Massive IBD market. $50–100M. 🧬 SER-147: Preclinical program targeting serious infections in chronic liver disease/cirrhosis. $15–40M. That’s roughly $390M–$815M of potential risk-adjusted pipeline value by my estimates — BEFORE assigning value to the broader platform/IP or future indications.
0 replies